FMC (US:FMC) Prnewswire·2026-02-04 22:00Core Insights - FMC Corporation announced its 2026 operational priorities, focusing on strengthening its balance sheet and exploring strategic options to enhance shareholder value [2][3][5] Financial Performance - For the fourth quarter of 2025, FMC reported revenue of $1.08 billion, a decline of 12% compared to the fourth quarter of 2024, with a 6% price decline primarily due to Rynaxypyr® [13][14] - The full year 2025 revenue was $3.47 billion, an 18% decrease from 2024, driven by a 6% price decline and competitive pressures [16][17] - Adjusted EBITDA for 2025 was $843 million, down 7% year-over-year, with favorable costs offset by price declines and the removal of India sales [18] 2026 Outlook - FMC's revenue guidance for 2026 is projected between $3.60 billion and $3.80 billion, reflecting a 5% decline at the midpoint compared to the previous year [6] - Adjusted EBITDA for 2026 is expected to be between $670 million and $730 million, a 17% decrease from the prior year [7] - Adjusted EPS for 2026 is forecasted to be between $1.63 and $1.89, a decrease of 41% compared to the previous year [7] Strategic Initiatives - The company plans to pay down $1 billion in debt through asset sales and licensing agreements, including the sale of its India commercial business [3][4] - FMC aims to improve the competitiveness of its core portfolio and manage the post-patent transition for Rynaxypyr® while advancing the commercialization of new active ingredients [3][4] Market Dynamics - The anticipated decline in revenue is attributed to lower prices and reduced orders from diamide partners, with India representing a 2% headwind [6] - Sales of new active ingredients are expected to grow significantly, projected between $300 million and $400 million, marking over 75% growth at the midpoint compared to the previous year [6]